HUP1900193A1 - Szelektív hisztamin H3 receptor antagonista savaddíciós sók és eljárás elõállításukra - Google Patents

Szelektív hisztamin H3 receptor antagonista savaddíciós sók és eljárás elõállításukra

Info

Publication number
HUP1900193A1
HUP1900193A1 HU1900193A HUP1900193A HUP1900193A1 HU P1900193 A1 HUP1900193 A1 HU P1900193A1 HU 1900193 A HU1900193 A HU 1900193A HU P1900193 A HUP1900193 A HU P1900193A HU P1900193 A1 HUP1900193 A1 HU P1900193A1
Authority
HU
Hungary
Prior art keywords
histamin
selective
preparation
acid
addition salts
Prior art date
Application number
HU1900193A
Other languages
English (en)
Inventor
Aniko Dr Meiszterics
Ferenc Endre Seboek
Adam Dr Demeter
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Priority to HUP1900193A priority Critical patent/HU231335B1/hu
Priority to PCT/IB2020/055105 priority patent/WO2020240490A1/en
Priority to JP2021570822A priority patent/JP2022534974A/ja
Priority to CN202080040296.3A priority patent/CN113906016A/zh
Priority to CA3141698A priority patent/CA3141698A1/en
Priority to US17/615,176 priority patent/US20220235030A1/en
Priority to EP20730747.1A priority patent/EP3976598B1/en
Publication of HUP1900193A1 publication Critical patent/HUP1900193A1/hu
Publication of HU231335B1 publication Critical patent/HU231335B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUP1900193A 2019-05-31 2019-05-31 Szelektív hisztamin H3 receptor antagonista savaddíciós sók és eljárás előállításukra HU231335B1 (hu)

Priority Applications (7)

Application Number Priority Date Filing Date Title
HUP1900193A HU231335B1 (hu) 2019-05-31 2019-05-31 Szelektív hisztamin H3 receptor antagonista savaddíciós sók és eljárás előállításukra
PCT/IB2020/055105 WO2020240490A1 (en) 2019-05-31 2020-05-29 Selective histamine h3 antagonist acid addition salts and process for the preparation thereof
JP2021570822A JP2022534974A (ja) 2019-05-31 2020-05-29 選択的ヒスタミンｈ３アンタゴニスト酸付加塩およびその調製方法
CN202080040296.3A CN113906016A (zh) 2019-05-31 2020-05-29 选择性组胺h3拮抗剂酸加成盐及其制备方法
CA3141698A CA3141698A1 (en) 2019-05-31 2020-05-29 Selective histamine h3 antagonist acid addition salts and process for the preparation thereof
US17/615,176 US20220235030A1 (en) 2019-05-31 2020-05-29 Selective histamine h3 antagonist acid addition salts and process for the preparation thereof
EP20730747.1A EP3976598B1 (en) 2019-05-31 2020-05-29 Selective histamine h3 antagonist acid addition salts and process for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUP1900193A HU231335B1 (hu) 2019-05-31 2019-05-31 Szelektív hisztamin H3 receptor antagonista savaddíciós sók és eljárás előállításukra

Publications (2)

Publication Number Publication Date
HUP1900193A1 true HUP1900193A1 (hu) 2020-12-28
HU231335B1 HU231335B1 (hu) 2023-01-28

Family

ID=89992918

Family Applications (1)

Application Number Title Priority Date Filing Date
HUP1900193A HU231335B1 (hu) 2019-05-31 2019-05-31 Szelektív hisztamin H3 receptor antagonista savaddíciós sók és eljárás előállításukra

Country Status (7)

Country Link
US (1) US20220235030A1 (hu)
EP (1) EP3976598B1 (hu)
JP (1) JP2022534974A (hu)
CN (1) CN113906016A (hu)
CA (1) CA3141698A1 (hu)
HU (1) HU231335B1 (hu)
WO (1) WO2020240490A1 (hu)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists

Also Published As

Publication number Publication date
EP3976598C0 (en) 2024-03-27
HU231335B1 (hu) 2023-01-28
US20220235030A1 (en) 2022-07-28
CN113906016A (zh) 2022-01-07
EP3976598B1 (en) 2024-03-27
EP3976598A1 (en) 2022-04-06
WO2020240490A1 (en) 2020-12-03
CA3141698A1 (en) 2020-12-03
JP2022534974A (ja) 2022-08-04

Similar Documents

Publication Publication Date Title
IL283362A (en) A thrbeta receptor agonist compound and a method for its preparation and use
IL284446A (en) A method for preparing a dual gip/glp1 agonist
LT3610875T (lt) Opioido (mor) agonisto druska, jo fumarato druskos i kristalinė forma ir jos gavimo būdas
IL281464A (en) Crystal forms of a paranoid X receptor agonist
EP3965765A4 (en) OPIOID RECEPTOR ANTAGONIST PRODRUGS
IL292639A (en) Heterocyclic nmda antagonist
GB2603330B (en) Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
EP3638282A4 (en) HYDROCHLORIDE SALTS OF C5A RECEPTORAGONIST PEPTIDES
SG11202007896YA (en) Compounds having s1p5 receptor agonistic activity
HUP1900193A1 (hu) Szelektív hisztamin H3 receptor antagonista savaddíciós sók és eljárás elõállításukra
IL289066A (en) Preparations and methods for treating acute cannabinoid overdose using a cannabinoid receptor antagonist
IL286054A (en) A process for the preparation of a modified imidazoquinoline
IL264708B (en) History of n-[2-(4-phenoxypiperidin-1-yl)-2-(3,1-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2- (3,1-thiazol-5-yl)ethyl]benzamide-modified p2x7 receptor antagonists
ZA202101279B (en) A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride
EP3803035C0 (en) MODULAR HEAD FOR WELL TUBES
PT3643704T (pt) Novos intermediários para a preparação de hidrocloreto de remifentanil
PL3720841T3 (pl) Sposób otrzymywania kryształów hydratu chlorowodorku l-cysteiny naturalnej za pomocą chromatografii ciągłej
EP3681880A4 (en) PROCESS FOR THE PREPARATION OF CRYSTALLINE TIPIRACIL HYDROCHLORIDE
PT3819293T (pt) Antagonista do receptor 2 da angiotensina na forma de sal e forma cristalina e método de preparação do mesmo
EP4324827A4 (en) PHARMACEUTICALLY ACCEPTABLE SALT OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST AND CRYSTALLINE FORM THEREOF
GB201910515D0 (en) GLP-1 Receptor antagonists
HUP1800089A2 (en) Process for the preparation of the b polymorph form of treprostinil-diethanol-amine salt